EGFR and non-small cell lung carcinoma: So far, EGFR-TKIs have been widely used for advanced NSCLC irrespective of the EGFR mutation status because earlier trials that demonstrated the efficacy of EGFR-TKIs for second- or third-line therapy of advanced NSCLC did not consider EGFR genotype.